India Court Allows Dr. Reddy’s to Export Generics of Novo Nordisk’s Semaglutide Drug
An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.
By Shruti Mahajan, Satviki Sanjay · Bloomberg Markets
An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.